Predicting the Development of Renal Replacement Therapy Indications by Combining the Furosemide Stress Test and Chemokine (C-C Motif) Ligand 14 in a Cohort of Postsurgical Patients

OBJECTIVES: Optimal timing of renal replacement therapy (RRT) initiation in severe acute kidney injury (AKI) remains controversial. Initiation of treatment early in the course of AKI may lead to some patients undergoing unnecessary RRT, whereas delayed treatment is associated with increased mortality. This study aims to investigate whether the combination of the furosemide stress test (FST) and AKI-associated biomarkers can predict the development of indications for RRT. DESIGN: Single-center, prospective, observational study. SETTING: University Hospital of Muenster, Germany. PATIENTS: Critically ill, postoperative patients with moderate AKI (Kidney Disease: Improving Global Outcomes stage 2) and risk factors for further progression (vasopressors and/or mechanical ventilation) receiving an FST. INTERVENTIONS: Sample collection and measurement of different biomarkers (chemokine [C-C motif] ligand 14 [CCL14], neutrophil gelatinase-associated lipocalin, dipeptidyl peptidase 3). MEASUREMENT AND MAIN RESULTS: The primary endpoint was the development of greater than or equal to one predefined RRT indications (hyperkalemia [≥ 6 mmol/L], diuretic-resistant hypervolemia, high urea serum levels [≥ 150 mg/dL], severe metabolic acidosis [pH ≤ 7.15], oliguria [urinary output < 200 mL/12 hr], or anuria). Two hundred eight patients were available for the primary analysis with 108 having a negative FST (urine output < 200 mL in 2 hr following FST). Ninety-eight patients (47%) met the primary endpoint, 82% in the FST negative cohort. At the time of inclusion, the combination of a negative FST test and high urinary CCL14 levels had a significantly higher predictive value for the primary endpoint with an area under the receiver operating characteristic curve (AUC) of 0.87 (95% CI, 0.82–0.92) compared with FST or CCL14 alone (AUC, 0.79; 95% CI, 0.74–0.85 and AUC, 0.83; 95% CI, 0.77–0.89; p < 0.001, respectively). Other biomarkers showed lower AUCs. CONCLUSIONS: The combination of the FST with the renal biomarker CCL14 predicts the development of indications for RRT.

[1]  J. Kellum,et al.  Performance of a Standardized Clinical Assay for Urinary C–C Motif Chemokine Ligand 14 (CCL14) for Persistent Severe Acute Kidney Injury , 2022, Kidney360.

[2]  L. Forni,et al.  Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative , 2021, Nature Reviews Nephrology.

[3]  S. Besset,et al.  Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial , 2021, The Lancet.

[4]  L. Forni,et al.  Comparison of C-C motif chemokine ligand 14 with other biomarkers for adverse kidney events after cardiac surgery. , 2021, The Journal of thoracic and cardiovascular surgery.

[5]  Javier A. Neyra,et al.  Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. , 2020, The New England journal of medicine.

[6]  L. Forni,et al.  Biomarker-guided implementation of the KDIGO guidelines to reduce the occurrence of acute kidney injury in patients after cardiac surgery (PrevAKI-multicentre): protocol for a multicentre, observational study followed by randomised controlled feasibility trial , 2020, BMJ Open.

[7]  L. Forni,et al.  Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study , 2020, Intensive Care Medicine.

[8]  S. Bagshaw,et al.  The furosemide stress test for prediction of worsening acute kidney injury in critically ill patients: A multicenter, prospective, observational study. , 2019, Journal of critical care.

[9]  D. Annane,et al.  Timing of Renal‐Replacement Therapy in Patients with Acute Kidney Injury and Sepsis , 2018, The New England journal of medicine.

[10]  J. Kellum,et al.  Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial) , 2018, Critical Care.

[11]  S. Bagshaw,et al.  Biomarkers for prediction of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis , 2018, Intensive Care Medicine.

[12]  R. Bellomo,et al.  Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment , 2017, Nature Reviews Nephrology.

[13]  B. Banas,et al.  Biomarker-guided Intervention to Prevent Acute Kidney Injury After Major Surgery: The Prospective Randomized BigpAK Study , 2017, Annals of surgery.

[14]  A. Hoffmeier,et al.  Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial , 2017, Intensive Care Medicine.

[15]  J. Kellum,et al.  Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. , 2016, JAMA.

[16]  F. Tubach,et al.  Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. , 2016, The New England journal of medicine.

[17]  Rinaldo Bellomo,et al.  Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study , 2015, Intensive Care Medicine.

[18]  P. Kimmel,et al.  Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity. , 2015, Journal of the American Society of Nephrology : JASN.

[19]  P. Kimmel,et al.  Development and Standardization of a Furosemide Stress Test to Predict the Severity of Acute Kidney Injury , 2013, Critical Care.

[20]  A. Khwaja KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.